# Research to access pathway for investigational drugs for COVID-19 (RAPID C-19) oversight group

The RAPID C-19 oversight group reviews the briefing document prepared by NICE (supported by the SMC through collaborative working) to see whether the current evidence base supports the use of that treatment for COVID-19.

If there is strong evidence which shows the treatment to be effective, the oversight group determines what preparations are needed for patient access and their assessment of the evidence, along with suggested next steps.

Where the evidence of efficacy is uncertain but there are ongoing clinical trials, the topic will continue to be monitored and will be considered again by the oversight group when the results of these trials become available.

For treatments where the evidence does not support their use in COVID-19 and no further evidence is expected, the topic is not prioritised for active monitoring but can be brought back to the oversight group if new evidence emerges.

# Oversight group membership

The RAPID C-19 oversight group is chaired by the programme director for commercial and managed access at NICE. The role of the chair is to facilitate the meeting.

## NHS England and NHS Improvement

James Palmer - National Medical Director, Specialised Services

### Specialised commissioning

* Programme Director (Clinical Strategy)
* Clinical Director, National Clinical Policy
* Pharmacy Lead
* National Clinical Policy Lead
* National Clinical Policy Fellow

## Medicines and Healthcare products Regulatory Agency (MHRA)

Krishna Prasad - Deputy Director (Interim) Licensing Division, MHRA, Principal Assessor to Commission on Human Medicines (CHM)

* Expert Medical Assessor, Licensing Division

## National Institute for Health Research (NIHR)

Daniel McAuley – Director NIHR Efficacy and Mechanism Evaluation (EME) Programme

## National Institute for Health and Care Excellence (NICE)

Meindert Boysen - Deputy Chief Executive and Director of the Centre for Health Technology Evaluation

### Centre for Health Technology Evaluation (including the Life Sciences Team)

* Programme Director - HTA methods and guidance
* Programme Director - Commercial and Managed Access
* Associate Director - Planning and Operations
* Accelerated Access Collaborative Relationship and Delivery Lead
* Senior Market Access Adviser, NICE Office for Market Access and Accelerated Access Collaborative Secretariat
* Market Access Adviser
* Market Access Analysts (3)
* Programme Manager
* Coordinator

### Centre for Guidelines

* Programme Director - Medicines and Technologies Programme

### Science, Evidence and Analytics Directorate

* Programme Director - Scientific Affairs

## Scottish Medicines Consortium (Healthcare Improvement Scotland)

* Chief Pharmaceutical Adviser
* Principal Pharmaceutical Analyst

## All Wales Therapeutics & Toxicology Centre (AWTTC)

* Head of Health Technology Appraisal, Medicines Management and Programme Director AWTTC
* Head of Welsh Analytical Prescribing Support Unit (WAPSU)

## Northern Ireland Health and Social Care Board

* Pharmacy Co-ordinator (Specialist Medicines)